|
|
The Women’s Health Market Outlook to 2011
CHAPTER 1: EPIDEMIOLOGY OF WOMEN’S
HEALTH
- Summary
- Introduction
- Osteoporosis
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
- Hormonal Contraception
- Overview
- Prescription and
management
- Epidemiology
- Forecast epidemiology
- Urinary Incontinence
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
- Common gynecological
infections
- Overview
- Candidiasis
- Vaginosis
- Trichomoniasis
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
- Hormone replacement therapies
- Overview
- Diagnosis, treatment and
management
- Epidemiology
- Forecast epidemiology
CHAPTER 2: GLOBAL MARKET ANALYSIS
- Summary
- Introduction
- Market analysis by country
- Licensing trends
- Market analysis by drug class
- Leading brands dynamics
- Key events in the market
- Bayer acquires Schering AG
to form Bayer-Schering Pharma
- Safety concerns associated
with the use of transdermal release system formulations of
hormonal contraceptives
- Association of jaw bone
necrosis with the long term use of bisphosphonates in the
treatment of
osteoporosis
- Arrival of generic
competition to market-leading anti-infectives treatments
- Launch of Plan B emergency
contraceptive in the US market
- Urinary incontinence market
analysis
- Market dynamics
- Key brands analysis
- Urinary incontinence sales
forecasts to 2011
- Anti-infectives market
analysis
- Market dynamics
- Key brands analysis
- Anti-infectives sales
forecasts to 2011
- Osteoporosis
- Leading brands of
Osteoporosis market
- Competitive dynamics of
subclasses of osteoporosis treatments
- Bisphosphonates market
analysis
- Market dynamics
- Key brands analysis
- Calcitonins
- Market dynamics
- Key brands analysis
- Osteoporosis sales
forecasts to 2012
- Hormonal contraception
- Competitive dynamics of
subclasses of hormonal contraceptives
- Leading brands of Hormonal
Contraceptives
- Key brands analysis
- Hormonal contraceptives
sales forecasts to 2012
- Hormone Replacement Therapy
- Competitive dynamics of
subclasses of the Hormone Replacement Therapy market
- Leading brands of Hormone
replacement therapies
- Market dynamics
- Key brands analysis
- Hormonal replacement
therapy sales forecasts to 2012
- Total Women’s health market
sales forecasts to 2011
CHAPTER 3: PIPELINE ANALYSIS
- Summary
- Introduction
- Key trends in R&D
- New drug delivery
formulations
- Reformulations
- Extended cycle regimes
- New dosing regime
- Second-generation
anticholinergics in urinary incontinence
- The women’s health pipeline
- Leading drugs in development
- Profiles of key pipeline
products
- Phase II compounds
- NBI-56418
- Nesterone
- Phase III compounds
- J867 (asoprisnil)
- Org 36286 (corifollitropin
alfa)
- Drugs in registration
- Pristiq (desvenlafaxine)
- Viviant (bazedoxifene)
- Evamist (estradiol MDTS)
- Lybrel/Librel/Anya (levonorgestrel/ethinyl
estradiol)
- Recently marketed drugs
- Seasonique (levonorgestrel/ethinyl
estradiol)
- Boniva (ibandronate)
- Yaz (drosperinone/ethinyl
estradiol)
- Novel anticholinergic
treatments
- Pipeline forecasts
- Contraception forecasts
- Osteoporosis forecasts
- Hormone replacement
forecasts
- Urinary incontinence
forecasts
- Anti-infectives forecasts
- Key trends
CHAPTER 4: COMPETITIVE LANDSCAPE
- Summary
- Introduction
- Company market shares
- Merck
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth
analysis
- Drivers of growth
- Resistors of growth
- Novartis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth
analysis
- Drivers of growth
- Resistors of growth
- Bayer-Schering Pharma
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth
analysis
- Drivers of growth
- Resistors of growth
|
